Skip to main content
Theraclion SA logo

Theraclion SA — Investor Relations & Filings

Ticker · ALTHE ISIN · FR0010120402 LEI · 9695007X7HA7A1GCYD29 PA Manufacturing
Open in API
Filings indexed 397 across all filing types
Latest filing 2025-02-20 Capital/Financing Update
Country FR France
Listing PA ALTHE

About Theraclion SA

https://www.theraclion.com/?_ga=2.14878…

Theraclion SA is a medical device company specializing in the development and marketing of non-invasive therapeutic solutions using High-Intensity Focused Ultrasound (HIFU). The company's technology, known as echotherapy, provides a non-surgical alternative for tissue ablation. Its flagship product, SONOVEIN®, is a robotic solution for the non-invasive treatment of varicose veins. The system uses external ultrasound beams to ablate the target vein without incisions, catheters, or sedation, allowing for immediate patient recovery. Theraclion also developed ECHOPULSE®, a system for the treatment of thyroid nodules and breast fibroadenomas. The company's core focus is on providing precise, non-invasive treatments that reduce risks and recovery time compared to traditional surgical procedures.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Opérations de l'émetteur (acquisitions, cessions...)
Capital/Financing Update Classification · 1% confidence The document is a press release from Theraclion announcing a new financing arrangement involving the issuance of convertible bonds (BEOCA/OCA) to existing shareholders. It details the terms of the capital raise, the impact on shareholding, and the use of proceeds. This falls under the category of company fundraising and capital structure changes.
2025-02-20 French
Inside Information / Other news releases
Regulatory Filings Classification · 1% confidence The document is a press release issued by Theraclion announcing a clinical milestone regarding their SONOVEIN technology. It does not fit into specific financial reporting categories like 10-K, IR, or ER, nor is it a regulatory filing for a specific corporate action like a dividend or share issue. As it is a general corporate announcement regarding R&D and clinical trials, it falls under the fallback category for regulatory announcements.
2025-02-11 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release from Theraclion announcing the clinical testing of a new 'SpeedPulse' feature for their SONOVEIN technology. It does not fit into specific financial reporting categories like 10-K, IR, or ER, nor is it a regulatory filing or a report publication announcement. As it is a general corporate announcement regarding product development and clinical trials, it falls under the 'Regulatory Filings' (RNS) category as the fallback for miscellaneous corporate news.
2025-02-11 French
Inside Information / News release on accounts, results
Earnings Release Classification · 1% confidence The document is titled "PUBLICATION OF ADJUSTED ACCOUNTS FOR THE FIRST HALF OF 2024" and presents detailed financial tables comparing initial and adjusted figures for the period ending June 30, 2024, against June 30, 2023. It includes key financial metrics like Turnover, Gross Margin, Net Income, and Operating Income for a six-month period. This structure and content strongly indicate a comprehensive financial report covering a period shorter than a full year. This aligns perfectly with the definition of an Interim / Quarterly Report (IR). Although it mentions the results have been subject to a limited review, it is the report itself, not just an announcement of its publication (RPA). H1 2024
2025-02-07 English
Informations privilégiées / Communiqué sur comptes, résultats
Earnings Release Classification · 1% confidence The document is a press release from Theraclion announcing the publication of adjusted financial accounts for the first half of 2024. It provides specific financial tables comparing the original and adjusted figures, explains the reason for the adjustment (a strategic shift and credit note issuance), and includes commentary on cash flow and going concern. While it contains financial data, it is an announcement of an adjustment to previously published interim results rather than the full interim report itself. Given the nature of the document as a corporate announcement of financial results/adjustments, it fits best under the Earnings Release (ER) category as it serves as the primary communication of these updated financial highlights. H1 2024
2025-02-07 French
Acquisition ou cession des actions de l'émetteur / Information relative au contrat de liquidité
Capital/Financing Update Classification · 1% confidence The document is titled "BILAN SEMESTRIEL S2 2024 DU CONTRAT DE LIQUIDITE CONTRACTE AVEC LE CREDIT INDUSTRIEL ET COMMERCIAL" (Semi-annual balance sheet S2 2024 of the liquidity contract with CIC). It details the holdings (shares and cash) in a liquidity account as of December 31, 2024, and summarizes the transactions (purchases and sales) during the second half of 2024. This type of regular reporting on market-making or liquidity provision activities, often required by stock exchanges, is a specific financial disclosure. It is not a full Annual Report (10-K), an Earnings Release (ER), or a standard Interim Report (IR). It most closely aligns with a specialized financial disclosure related to market stability or capital management. Given the options, it is a specific financial update related to market operations, but none perfectly match 'Liquidity Contract Report'. However, since it details the status of a contract and financial metrics related to share trading/management, it is a specialized financial disclosure. It is not a general regulatory filing (RNS) because it is highly specific. It is not a Capital/Financing Update (CAP) as it reports on existing arrangements, not new fundraising. It is a report detailing specific financial/contractual status, which fits best under the general umbrella of specialized financial reporting. Since there is no specific code for 'Liquidity Report', and it is a formal, periodic financial statement/update, it is closest to an Interim Report (IR) if we consider it a periodic financial disclosure, or potentially a Regulatory Filing (RNS) if it's a mandatory exchange filing. Given the detailed financial breakdown, classifying it as an Interim Report (IR) for a specific contractual period (S2 2024) is the most appropriate fit among the provided comprehensive report types, although it is highly specialized. If we strictly adhere to the definitions, it is a report detailing financial status over a period, similar in structure to an IR but focused on liquidity. I will classify it as an Interim Report (IR) as it is a comprehensive report for a defined period (H2 2024) detailing financial positions and activity, even if the subject is a liquidity contract rather than core operations.
2025-01-13 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.